Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery
Obesity · 2026-08 · 34 (8) · 1583-1591
DOI: 10.1002/oby.70246 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Obesity, online erschienen am 25.06.2026. Verfasst von Avery Brown und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA. Hauptthemen laut MEDLINE: Tirzepatide, Glucagon-Like Peptides, Bariatric Surgery, Obesity, Morbid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objective
Directly compare the real‐world effectiveness of semaglutide and tirzepatide to bariatric operations: sleeve gastrectomy and gastric bypass.
Methods
This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP‐1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024. Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models. Intention‐to‐treat (any GLP‐1RA) and per‐protocol (1 year of continuous GLP‐1RA orders) analyses were performed.
Results
Of 44,025 patients studied, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years post treatment: semaglutide ( n = 25,804) TWL (95% CI): 5.4% (5.3%–5.6%), 6.5% (6.4%–6.7%), and 7.4% (7.3%–7.6%); tirzepatide ( n = 7308): 9.1% (8.9%–9.4%) and 10.8% (10.2%–11.3%); sleeve gastrectomy ( n = 8728): 24.4% (24.3%–24.6%), 22.4% (22.3%–22.5%), and 22.0% (21.8%–22.1%); gastric bypass ( n = 2185): 29.8% (29.7%–29.9%), 28.1% (28.0%–28.2%), and 28.4% (28.3%–28.5%). With 1 year of continuous GLP‐1RA, findings were: semaglutide TWL: 7.2% (7.0%–7.4%), 8.0% (7.8%–8.2%), and 8.8% (8.6%–9.0%); tirzepatide TWL: 11.7% (11.4%–11.9%) and 11.9% (11.5%–12.3%).
Conclusions
In this retrospective two‐center study, bariatric surgery was associated with greater weight loss than GLP‐1RAs among patients eligible for both options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA.
- Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
- Center for Surgical and Transplant Applied Research, NYU Langone Health, New York, New York, USA.
- Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Surgery, NYU Langone Hospital-Brooklyn, Brooklyn, New York, USA.
ORCID-Profile: Akio Kozato, Karan R Chhabra
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Brown, A., Patel, S. S., Kozato, A., Orandi, B. J., Massie, A., Vu, A. H., Somoza, E., Mei, T., Desai, S., Zhang, D. S., Segev, D., Welcome, A. U., Ren-Fielding, C., Parikh, M., & Chhabra, K. R. (2026). Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity, 34(8), 1583-1591. https://doi.org/10.1002/oby.70246
Vancouver
Brown A, Patel SS, Kozato A, Orandi BJ, Massie A, Vu AH, et al. Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity. 2026;34(8):1583-1591. doi:10.1002/oby.70246
BibTeX
@article{Brown2026,
author = {Brown, Avery and Patel, Suhani S and Kozato, Akio and Orandi, Babak J and Massie, Allan and Vu, Alexander Hien and Somoza, Eduardo and Mei, Tony and Desai, Sunita and Zhang, Donglan S and Segev, Dorry and Welcome, Akuezunkpa Ude and Ren-Fielding, Christine and Parikh, Manish and Chhabra, Karan R},
title = {Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery},
journal = {Obesity},
year = {2026},
volume = {34},
number = {8},
pages = {1583--1591},
doi = {10.1002/oby.70246}
}
EUVIMED